What's behind Moderna's latest 9.8% stock pullback?

Traders Union
All News
Stocks
Moderna slides 9.78% today on losses

Highlights

Moderna draws attention in 2026 on its personalized mRNA cancer vaccine partnership with Merck, with Phase 3 trial data expected October 24.
The company faces ongoing losses and reduced COVID-19 vaccine sales, sustaining broader selling pressure on the stock.
Shares of Moderna are supported by strong bullish technical signals but trade near $212.22 after a near-10% drop; expected five-day range is $193.86 to $242.69.

Investor focus sharpens on trial data amid persistent pressure

Moderna recorded notable attention in 2026 following multiple news events relating to the company's personalized mRNA cancer vaccine collaboration with Merck targeting high-risk melanoma. Investors focused on anticipation of Phase 3 clinical trial data set for presentation on October 24. Ongoing losses and weaker COVID-19 vaccine sales also accompanied this period, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, believes Moderna’s drop signals mounting skepticism around its breakthrough narratives. He highlights that despite ongoing attention to the mRNA cancer vaccine and bullish technicals, repeated failures to hold above resistance point to shaky structural support. Sentiment remains fragile amid persistent losses and falling COVID-19 vaccine sales. Kharitonov warns that technical overextensions, such as an elevated RSI and increased volatility, set the stage for further correction. He states, "Until fundamental results materialize, I see more risk of downside exhaustion than sustainable rallies in Moderna."

Viktoras Karapetjanc, expert at Traders Union, sees the broad sell-off as creating a strong setup for new buyers. He points to robust technical alignment and the market’s anticipation of positive Phase 3 vaccine data as key drivers. Karapetjanc notes Moderna holds its uptrend above all major moving averages, with momentum measures remaining supportive of further growth. Looking forward, he states, "I expect bullish structure to hold — a confirmed break above $217.66 could unlock further upside in the coming weeks."

Jainam Mehta, market strategist, notes that Moderna trades within a wide technical range after an abrupt drop. He observes rising volatility and momentum divergence, which could invite tactical entries for contrarian traders. Mehta points out that sideways movement near key support and resistance warrants defensive positioning. He says, "If volatility persists, patient traders should look for breakout signals around $217.66 or $193.86 for directional conviction."

Overbought signals emerge as bullish momentum faces resistance

Moderna is trading above its 20-day, 50-day, and 200-day moving averages ($197.87, $151.63, and $76.45), signaling sustained strength across all timeframes. The continued bullish alignment of the 50-day ahead of the 200-day average confirms the prevailing uptrend. Near-term resistance is found at $217.66 and immediate support at $205.13. Momentum measures remain robust: the MACD and ADX both point to continued buying, with an elevated RSI of 71.54 indicating potential overbought conditions. The CCI and Bull/Bear Power also signal overextension, and intraday price stands near session lows with volatility at 11.11%. Despite ongoing bullish technical signals, caution is warranted as prices show signs of pressure following the open.

Previously it was reported that Moderna faced continued resistance and downside risk even after key regulatory milestones and portfolio expansion. The current analysis signals that, despite robust technical positioning and heightened volatility ahead of major clinical trial data, the critical level to watch is the $217.66 resistance, where a confirmed breakout could catalyze further upside.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.